Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) attributable to Immudyne, Inc. $ (307,316) $ (262,025)
Net (loss) attributable to noncontrolling interests (68,924) (2,516)
Net (Loss) (376,240) (264,541)
Adjustments to reconcile net (loss) to net cash (used) by operating activities    
Change in fair value of derivative liability (873,830)
Bad debt recovery (44,543)
Amortization of debt discount 81,558
Loss on settlement of notes and other payables 634,325
Stock compensation expense 113,522 118,562
Common stock issued for services 160,833 230,000
Changes in Assets and Liabilities    
Trade accounts receivable (30,338) (296,638)
Other receivables 2,250
Product deposit (74,043)
Inventory 32,822 (118,204)
Accounts payable and accrued expenses (138,885) 254,159
Net cash (used) by operating activities (512,569) (76,662)
CASH FLOWS FROM FINANCING ACTIVITIES    
Investment in subsidiary by noncontrolling interest, net 63,378 79,130
Proceeds from notes payable 309,043
Repayment of convertible note payable (100,000)
Repayment of notes payable (176,420)
Sale of common stock and warrants 673,244
Purchase of treasury stock (3,151)
Net cash provided by financing activities 766,094 79,130
Net increase in cash 253,525 2,468
Cash at beginning of the period 182,561 232,984
Cash at end of the period 436,086 235,452
Supplemental Disclosure of Cash Flow Information    
Cash paid during the period for interest 3,612 5,813
Issuance of company stock for notes and other payables 242,192
Conversion of equity invested in subsidiary to common stock and warrants 272,203
Reclassification of options, warrants and other contracts to derivative liabilities upon issuance $ 1,636,590